Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Features of Invasive Aspergillosis Caused by Aspergillus flavus, France, 2012-2018

Lise Bertin-Biasutto et al. Emerg Infect Dis. 2025 May.

Abstract

Invasive aspergillosis (IA) caused by Aspergillus flavus remains poorly described. We retrospectively analyzed 54 cases of IA caused by A. flavus reported in France during 2012-2018. Among cases, underlying IA risk factors were malignancy, solid organ transplantation, and diabetes. Most (87%, 47/54) infections were localized, of which 33 were pleuropulmonary and 13 were ear-nose-throat (ENT) infection sites. Malignancy (70% [23/33]) and solid organ transplantation (21% [7/33]) were the main risk factors in localized pulmonary infections, and diabetes mellitus was associated with localized ENT involvement (61.5%, [8/13]). Fungal co-infections were frequent in pulmonary (36%, 12/33) but not ENT IA (0 cases). Antifungal monotherapy was prescribed in 45/50 (90%) cases, mainly voriconazole (67%, 30/45). All-cause 30-day case-fatality rates were 39.2% and 90-day rates were 47.1%, and rates varied according to risk factor, IA site, and fungal co-infections. Clinicians should remain vigilant for A. flavus and consider it in the differential diagnosis for IA.

Keywords: Aspergillus flavus; France; antimicrobial resistance; aspergillosis; fungi; immunosuppression; invasive fungal infections; respiratory infections.

PubMed Disclaimer

References

    1. Bretagne S, Sitbon K, Desnos-Ollivier M, Garcia-Hermoso D, Letscher-Bru V, Cassaing S, et al.; French Mycoses Study Group. Active surveillance program to increase awareness on invasive fungal diseases: the French RESSIF Network (2012 to 2018). MBio. 2022;13:e0092022. 10.1128/mbio.00920-22 - DOI - PMC - PubMed
    1. Chakrabarti A, Kaur H, Savio J, Rudramurthy SM, Patel A, Shastri P, et al. Epidemiology and clinical outcomes of invasive mould infections in Indian intensive care units (FISF study). J Crit Care. 2019;51:64–70. 10.1016/j.jcrc.2019.02.005 - DOI - PubMed
    1. Chakrabarti A, Chatterjee SS, Das A, Shivaprakash MR. Invasive aspergillosis in developing countries. Med Mycol. 2011;49(Suppl 1):S35–47. 10.3109/13693786.2010.505206 - DOI - PubMed
    1. Zanganeh E, Zarrinfar H, Rezaeetalab F, Fata A, Tohidi M, Najafzadeh MJ, et al. Predominance of non-fumigatus Aspergillus species among patients suspected to pulmonary aspergillosis in a tropical and subtropical region of the Middle East. Microb Pathog. 2018;116:296–300. 10.1016/j.micpath.2018.01.047 - DOI - PubMed
    1. Ragozzino S, Goldenberger D, Wright PR, Zimmerli S, Mühlethaler K, Neofytos D, et al. Distribution of Aspergillus species and prevalence of azole resistance in respiratory samples from Swiss tertiary care hospitals. Open Forum Infect Dis. 2021;9:ofab638. 10.1093/ofid/ofab638 - DOI - PMC - PubMed

Substances